/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Galapagos NV

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$31.77 0.0134(1.34%) GLPG at 04 Dec 2025 04:33 PM Biotechnology
Lowest Today 31.19
Highest Today 31.76
Today’s Open 31.23
Prev. Close 31.35
52 Week High 37.78
52 Week Low 22.36
Day’s Range: Low 31.19 High 31.76
52-Week Range: Low 22.36 High 37.78
1 day return -
1 Week return +1.14
1 month return +3.93
3 month return -0.59
6 month return +10.55
1 year return +17.43
3 year return -18.57
5 year return -73.93
10 year return -

Institutional Holdings

TANG CAPITAL MANAGEMENT LLC 6.06

Madison Avenue Partners, LP 2.85

Prosight Management, LP 2.69

FMR Inc 2.35

EcoR1 Capital, LLC 1.57

Hudson Bay Capital Management LP 0.78

Segall Bryant & Hamill 0.76

Renaissance Technologies Corp 0.71

Fidelity Advisor Equity Growth I 0.65

Fidelity VIP Growth Initial 0.60

Point72 Asset Management, L.P. 0.52

UBS Group AG 0.36

Fidelity Growth Discovery 0.35

BlackRock Inc 0.34

Millennium Management LLC 0.29

iShares Biotechnology ETF 0.28

Columbia VP Overseas Core 3 0.27

D. E. Shaw & Co LP 0.23

PRIMECAP Management Company 0.22

Dafna Capital Management LLC 0.20

NORGES BANK 0.18

Segall Bryant & Hamill Sm Cp Val Ins 0.17

PRIMECAP Odyssey Aggressive Growth 0.15

Centiva Capital LP 0.14

VOLORIDGE INVESTMENT MANAGEMENT, LLC 0.13

Royal Bank of Canada 0.12

Tower Research Capital LLC 0.12

VP Partners Small Cap Value 3 0.07

Pacific Select Large-Cap Growth I 0.07

Columbia Overseas Core Institutional 3 0.07

Steward Values Enhanced International I 0.07

Fidelity Advisor Series Equity Gr 0.07

Vanguard US Opportunities Ins USD Acc 0.07

ALPS Medical Breakthroughs ETF 0.05

Avantis International Equity ETF 0.03

ERSTE STOCK BIOTEC EUR R01 A 0.02

ActivePassive International Equity ETF 0.02

Fidelity Equity Growth K6 0.01

iShares Nasdaq US Biotech ETF USD Acc 0.01

Barometer Global Equity Fund A 0.01

Market Status

Strong Buy: 0

Buy: 0

Hold: 4

Sell: 1

Strong Sell: 1

Fundamentals

Market Cap 2096.08 M

PB Ratio 0.7278

PE Ratio 0.0

Enterprise Value -1487.00 M

Total Assets 4135.72 M

Volume 57767

Company Financials

Annual Revenue FY23:543968000 544.0M, FY22:505280000 505.3M, FY21:484846000 484.8M, FY20:478053000 478.1M, FY19:844986000 845.0M

Annual Profit FY23:526287000 526.3M, FY22:493201000 493.2M, FY21:483217000 483.2M, FY20:478053000 478.1M, FY19:417666000 417.7M

Annual Net worth FY23:-153069000 -153.1M, FY22:-217991000 -218.0M, FY21:-125422000 -125.4M, FY20:-311001000 -311.0M, FY19:149845000 149.8M

Quarterly Revenue Q3/2025:71161000 71.2M, Q2/2025:65288000 65.3M, Q1/2025:74977000 75.0M, Q3/2024:59849000 59.8M, Q2/2024:77873000 77.9M

Quarterly Profit Q3/2025:338342000 338.3M, Q2/2025:60582000 60.6M, Q1/2025:61248000 61.2M, Q3/2024:59830000 59.8M, Q2/2024:61316001 61.3M

Quarterly Net worth Q3/2025:-202111000 -202.1M, Q2/2025:-105748000 -105.7M, Q1/2025:-153403000 -153.4M, Q3/2024:-50430000 -50.4M, Q2/2024:8985000 9.0M

Fund house & investment objective

Company Information Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Organisation Biotechnology

Employees 704

Industry Biotechnology

CEO Mr. Henry Gosebruch

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow